Any material, compound, mixture, or preparation that contains xylazine is a Schedule III controlled drug or substance, except in the following cases:
(1) Dispensing, prescribing, or administering, to an animal, a drug containing xylazine that has been approved by the United States secretary of health and human services under 21 U.S.C. § 360b (January 1, 2024);(2) Dispensing, prescribing, or administering xylazine to an animal that is permissible under 21 U.S.C. § 360b(a)(4) (January 1, 2024);(3) Manufacturing, distributing, or using xylazine as an active pharmaceutical ingredient for manufacturing an animal drug: (a) Approved under 21 U.S.C. § 360b (January 1, 2024); or(b) Issued an investigation use exemption under 21 U.S.C. § 360b(j) (January 1, 2024);(4) Manufacturing, distributing, or using a xylazine bulk chemical for pharmaceutical compounding by a licensed pharmacist or veterinarian; or(5) Any other use approved or permissible under 21 U.S.C. § 301, et seq. (January 1, 2024). SL 2024, ch 131, §1, eff. Feb. 12, 2024.Added by S.L. 2024, ch. 131,s. 1, eff. 2/12/2024.